rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    XLO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Xilio Therapeutics at Stifel 2026 Healthcare Conference: pipeline gains
      Nov 10Investing.comXLOSF
      Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
      Nov 10Yahoo FinanceXLO
      Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
      Nov 3Yahoo FinanceXLOSF
      Xilio doses first patient in lung cancer trial of XTX501
      Oct 26Investing.comXLO
      Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
      Oct 26Yahoo FinanceXLO
      Raymond James initiates Xilio Therapeutics stock with outperform rating
      Oct 21Investing.comXLO
      Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 2Yahoo FinanceXLO
      Xilio Therapeutics appoints Yariv Houvras as chief medical officer
      Sep 28Investing.comXLO
      Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

      Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncologyWALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Dr. Yariv Houvras as chief medical officer. “We are thrill

      Sep 28Yahoo FinanceXLO
      Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.88

      Sep 2Yahoo FinanceXLO

      This is the newest page. Registered accounts read further back.